United Kingdom

Profile: Bio Path Holdings Inc (BPTH.OQ)

BPTH.OQ on NASDAQ Stock Exchange Capital Market

18 Apr 2019
Change (% chg)

$-1.20 (-5.93%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. The Company's drug delivery and antisense technology, called DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a neutral charged lipid bilayer. In vivo, the DNAbilize delivered antisense drug substances are systemically distributed across the body to allow for reduction or elimination of proteins in blood diseases and solid organs. Using DNAbilize as a platform for drug manufacturing, the Company has approximately two antisense drug candidates in development to treat a total of over five different disease indications.

The Company's lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). BP1001 is in Phase II clinical trials for acute myeloid leukemia (AML), and for blast phase and accelerated phase chronic myelogenous leukemia (CML). BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC). The Company has also completed Phase I clinical trials for BP1001 for indications for Myelodysplastic Syndrome (MDS) and Acute Lymphoblastic Leukemia (ALL). The Company's other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1002 is in preparation for an Investigational New Drug (IND) application. BP1002 is intended to target the lymphoma and certain solid tumor markets. Clinical targets for BP1002 include lymphoma, breast cancer, colon cancer, prostate cancer and leukemia.

Company Address

Bio Path Holdings Inc

4710 Bellaire Blvd Ste 210
BELLAIRE   TX   77401-4505
P: +1832.7421357

Company Web Links